AEON Biopharma, Inc. (AEON) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AEON SEC filings page.
This page shows AEON Biopharma, Inc. (AEON) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
AEON remains a development-stage business whose operations currently depend on external funding, with liabilities far exceeding its asset base.
FY2025 operating cash flow of-$17.3M nearly matched the$12.8M operating loss, so reported losses translated into cash needs rather than a mainly non-cash accounting gap. Financing inflow of$20.3M then exceeded that cash need, pointing to external funding as the operating model’s current support.
The spending mix changed materially: R&D fell from
FY2025 liabilities were roughly eleven times assets, at
Financial Health Signals
AEON Biopharma, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
AEON Biopharma, Inc.'s EBITDA was -$5.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 36.6% from the same quarter a year earlier. Against the prior quarter it is up 0.3%.
AEON Biopharma, Inc. reported -$1.2M in net income in Q2 2026. This represents an increase of 82.6% from the same quarter a year earlier. Against the prior quarter it is up 90.2%.
Not reported for Q2 2026.
Cash & Balance Sheet
AEON Biopharma, Inc. held $3.4M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
AEON Biopharma, Inc. invested $2.9M in research and development in Q2 2026. This represents an increase of 176.1% from the same quarter a year earlier. Against the prior quarter it is up 44.4%.
Not reported for Q2 2026.
Not reported for Q2 2026.
AEON Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $2.9M+176.1% | $2.0M+146.5% | N/A | $597K-38.6% | $1.1M-76.0% | $825K-85.6% | N/A | $972K-84.8% |
| SG&A Expenses | $3.0M-8.2% | $3.9M+24.9% | N/A | $1.9M-36.5% | $3.3M-1.9% | $3.1M-32.8% | N/A | $3.0M-42.2% |
| Operating Income | -$5.9M-36.4% | -$5.9M-1184.2% | N/A | -$2.5M+37.9% | -$4.3M | -$462K | N/A | -$4.0M |
| EBITDA | -$5.9M-36.6% | -$5.9M-1235.0% | N/A | -$2.5M+38.0% | -$4.3M | -$443K | N/A | -$4.0M |
| Net Income | -$1.2M+82.6% | -$11.8M-229.7% | N/A | -$4.5M+26.5% | -$6.6M | $9.1M | N/A | -$6.2M |
| EPS (Basic) | -$0.02+96.7% | -$0.29-112.7% | -$3.72-104.9% | -$0.39+96.5% | -$0.60-100.2% | $2.28+101.0% | $76.70 | -$11.24-40.3% |
| EPS (Diluted) | -$0.02 | -$0.29 | -$3.72 | -$0.39 | -$0.60 | $2.28 | $71.96 | -$11.24-40.3% |
| Diluted Shares (Avg) | 51M | 41M | N/A | 12M | 11M | 4M | N/A | 549,175-98.5% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
AEON Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.9M-49.3% | $8.6M-37.5% | $5.6M+77.0% | $8.7M+118.1% | $11.7M+103.4% | $13.8M+355.1% | $3.1M-54.1% | $4.0M-77.3% |
| Current Assets | $4.0M-61.1% | $6.6M-46.2% | $3.4M+113.7% | $7.4M+212.6% | $10.3M+155.3% | $12.3M+393.2% | $1.6M-74.4% | $2.4M-86.0% |
| Cash & Equivalents | $3.4M-59.3% | $6.2M-40.2% | $3.0M+23023.1% | $5.9M+1003.7% | $8.4M+145.2% | $10.4M+570.5% | $13K-99.7% | $537K-96.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $21.3M-22.7% | $25.4M+1.0% | $60.6M+91.1% | $28.6M-20.7% | $27.5M-18.3% | $25.1M-87.5% | $31.7M-80.2% | $36.1M-75.3% |
| Current Liabilities | $7.3M-19.6% | $6.7M-22.8% | $6.9M-51.3% | $8.2M-23.3% | $9.1M-12.5% | $8.6M-45.9% | $14.1M+8.4% | $10.7M-24.3% |
| Non-Current Liabilities | $13.9M-24.2% | $18.7M+13.5% | $53.7M+205.7% | $20.4M-19.7% | $18.4M-20.9% | $16.5M-91.1% | $17.6M-88.0% | $25.4M-80.8% |
| Total Equity | -$15.4M+3.1% | -$16.8M-47.9% | -$55.0M-92.6% | -$19.9M+38.1% | -$15.9M+43.3% | -$11.3M+94.3% | -$28.6M+81.3% | -$32.1M+75.0% |
| Retained Earnings | -$483.8M-12.7% | -$482.6M-14.2% | -$470.8M-9.1% | -$433.7M0.0% | -$429.1M-0.4% | -$422.5M+28.6% | -$431.6M+8.9% | -$433.7M+3.1% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
AEON Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.7M-76.9% | -$2.6M+66.7% | -$4.7M-658.8% | -$2.6M+12.1% | -$2.1M+74.2% | -$7.9M+8.0% | -$621K+94.4% | -$3.0M+80.4% |
| Depreciation & Amortization | $20K0.0% | $19K0.0% | $20K-13.0% | $19K-24.0% | $20K-16.7% | $19K-24.0% | $23K-4.2% | $25K+19.0% |
| Stock-Based Compensation | $1.9M+11.8% | $1.9M+11.7% | N/A | $1.0M-37.5% | $1.7M0.0% | $1.7M+6.7% | N/A | $1.6M-26.3% |
| Capital Expenditures | N/A | N/A | $0 | $0 | $0 | $4K | N/A | N/A |
| Free Cash Flow | N/A | N/A | -$4.7M | -$2.6M | -$2.1M | -$7.9M | N/A | N/A |
| Investing Cash Flow | N/A | N/A | $0 | $0 | $0 | -$4K | N/A | N/A |
| Financing Cash Flow | $886K+954.8% | $5.9M-68.0% | $1.8M+1746.4% | $84K+68.0% | $84K-99.2% | $18.3M+266.9% | $97K | $50K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
AEON Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$55.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.49), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| AEON Biopharma, Inc. AEON | FY2025 | N/A | N/A | N/A | $13.5M | — |
| Aprea Therapeutics, Inc. APRE | FY2025 | N/A | -$12.6M | N/A | $8.8M | — |
| COSCIENS Biopharma Inc. CSCI | FY2025 | $7.5M | -$10.4M | N/A | $8.6M | 34/100 |
| Processa Pharmaceuticals, Inc. PCSA | FY2025 | N/A | $13.6M | N/A | $4.5M | — |
| Dogwood Therapeutics, Inc. DWTX | FY2025 | N/A | -$34.3M | N/A | $49.6M | — |
| TransCode Therapeutics, Inc. RNAZ | FY2025 | N/A | -$34.7M | N/A | $26.6M | — |
Where AEON Biopharma, Inc. Ranks
Frequently Asked Questions
What is AEON Biopharma, Inc.'s EBITDA?
AEON Biopharma, Inc. (AEON) had EBITDA of -$12.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is AEON Biopharma, Inc.'s free cash flow?
AEON Biopharma, Inc. (AEON) recorded an outflow of $17.3M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is AEON Biopharma, Inc.'s operating cash flow?
AEON Biopharma, Inc. (AEON) recorded an outflow of $17.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are AEON Biopharma, Inc.'s total assets?
AEON Biopharma, Inc. (AEON) had $5.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are AEON Biopharma, Inc.'s capital expenditures?
AEON Biopharma, Inc. (AEON) invested $4K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does AEON Biopharma, Inc. spend on research and development?
AEON Biopharma, Inc. (AEON) invested $4.1M in research and development during fiscal year 2025.
What is AEON Biopharma, Inc.'s current ratio?
AEON Biopharma, Inc. (AEON) had a current ratio of 0.49 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is AEON Biopharma, Inc.'s P/E ratio?
AEON Biopharma, Inc. (AEON) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $13.5M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is AEON Biopharma, Inc.'s price-to-sales ratio?
AEON Biopharma, Inc. (AEON) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $13.5M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does AEON Biopharma, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, AEON Biopharma, Inc. (AEON) held $3.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $17.3M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is AEON Biopharma, Inc.'s debt-to-equity ratio negative or not reported?
AEON Biopharma, Inc. (AEON) has negative shareholder equity of -$55.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.